TriangleNCT00899847 · OUTCOME
Median Time to Engraftment After Auto-PBSC Transplant
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Days
- Interval / dispersion
- Full Range
- Time frame
- 1 month
What was measured
Engraftment is assessed as: * Neutrophil engraftment is \> 0.5 x 10⁹/L after cytopenia * Platelet engraftment is \> 20 x 10⁹/L after cytopenia
Analysis population: Includes all study participants
Groups in this outcome
Autologous-Allogeneic Hematopoietic Stem Cell Transplant
Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.
| Group | Source count |
|---|---|
| Autologous-Allogeneic Hematopoietic Stem Cell Transplant | 9 |
Reported measurements
Neutrophil Engraftment
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Autologous-Allogeneic Hematopoietic Stem Cell Transplant | 11 | Not reported | 10 | 12 | Not reported |
Platelet Engraftment
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Autologous-Allogeneic Hematopoietic Stem Cell Transplant | 15 | Not reported | 10 | 20 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 10
- upper Limit
- 12
- value
- 11
- title
- Neutrophil Engraftment
- categories
- measurements
- group Id
- OG000
- lower Limit
- 10
- upper Limit
- 20
- value
- 15
- title
- Platelet Engraftment
- denoms
- counts
- group Id
- OG000
- value
- 9
- units
- Participants
- description
- Engraftment is assessed as: * Neutrophil engraftment is \> 0.5 x 10⁹/L after cytopenia * Platelet engraftment is \> 20 x 10⁹/L after cytopenia
- dispersion Type
- Full Range
- groups
- description
- Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.
- id
- OG000
- title
- Autologous-Allogeneic Hematopoietic Stem Cell Transplant
- param Type
- MEDIAN
- population Description
- Includes all study participants
- reporting Status
- POSTED
- time Frame
- 1 month
- title
- Median Time to Engraftment After Auto-PBSC Transplant
- type
- SECONDARY
- unit Of Measure
- Days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice